{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:44:13Z","timestamp":1789595053707,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s11102-013-0475-3","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T09:20:12Z","timestamp":1362561612000},"page":"109-117","source":"Crossref","is-referenced-by-count":98,"title":["Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?"],"prefix":"10.1007","volume":"17","author":[{"given":"M.","family":"Barbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Albiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"475_CR1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","volume":"93","author":"CG Patil","year":"2008","unstructured":"Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER Jr (2008) Late recurrences of Cushing\u2019s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93:358\u2013362","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2005.02380.x","volume":"63","author":"AB Atkinson","year":"2005","unstructured":"Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B (2005) Long-term remission rates after pituitary surgery for Cushing\u2019s disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 63:549\u2013559","journal-title":"Clin Endocrinol (Oxf)"},{"key":"475_CR3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2265.2002.01511.x","volume":"56","author":"DA Rees","year":"2002","unstructured":"Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF (2002) Long-term follow-up results of transsphenoidal surgery for Cushing\u2019s disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 56:541\u2013551","journal-title":"Clin Endocrinol (Oxf)"},{"key":"475_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/neurosurgery\/47.6.1439","volume":"47","author":"JM Sheehan","year":"2000","unstructured":"Sheehan JM, Lopes MB, Sheehan JP, Ellegala D, Webb KM, Laws ER Jr (2000) Results of transsphenoidal surgery for Cushing\u2019s disease in patients with no histologically confirmed tumor. Neurosurgery 47:33\u201339","journal-title":"Neurosurgery"},{"key":"475_CR5","first-page":"3114","volume":"80","author":"D Bochicchio","year":"1995","unstructured":"Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing\u2019s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing\u2019s Disease Survey Group. J Clin Endocrinol Metab 80:3114\u20133120","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrendo.2011.12","volume":"7","author":"NA Tritos","year":"2011","unstructured":"Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7:279\u2013289","journal-title":"Nat Rev Endocrinol"},{"key":"475_CR7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM198709243171307","volume":"317","author":"N Sonino","year":"1987","unstructured":"Sonino N (1987) The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317:812\u2013818","journal-title":"N Engl J Med"},{"key":"475_CR8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1210\/edrv-7-4-409","volume":"7","author":"D Feldman","year":"1986","unstructured":"Feldman D (1986) Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 7:409\u2013420","journal-title":"Endocr Rev"},{"key":"475_CR9","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura E, Silva L, Agra R, Pontes L, Montenegro L, Albuquerque JL, Canadas V (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary 13:123\u2013129","journal-title":"Pituitary"},{"key":"475_CR11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BMK Biller","year":"2008","unstructured":"Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J et al (2008) Treatment of ACTH-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3171\/JNS\/2008\/108\/01\/0009","volume":"108","author":"BM Hoffman","year":"2008","unstructured":"Hoffman BM, Hlavac M, Martinez R, Buchfelder M, M\u00fcller OA, Fahlbusch R (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35\u00a0years. J Neurosurg 108:9\u201318","journal-title":"J Neurosurg"},{"key":"475_CR13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223\u2013230","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR14","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526\u20131540","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR15","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med 362:1846\u20131848","journal-title":"N Engl J Med"},{"key":"475_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115\u2013122","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide B2305 Study Group (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366:914\u2013924","journal-title":"N Engl J Med"},{"key":"475_CR18","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","volume":"97","author":"F Pecori Giraldi","year":"2012","unstructured":"Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, Scaroni C, Arvat E, Pontercorvi A, Cavagnini F (2012) Potential role for retinoic acid in patients with Cushing\u2019s disease. J Clin Endocrinol Metab 97:3577\u20133583","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","volume":"108","author":"M P\u00e1ez-Pereda","year":"2001","unstructured":"P\u00e1ez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Gr\u00fcbler Y, Missale C, Arzt E, Stalla GK (2001) Retinoic acid prevents experimental Cushing\u2019s syndrome. J Clin Invest 108:1123\u20131131","journal-title":"J Clin Invest"},{"key":"475_CR20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220\u2013240","journal-title":"Endocr Rev"},{"key":"475_CR21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1507\/endocrj1954.39.385","volume":"39","author":"LB Mercado-Asis","year":"1992","unstructured":"Mercado-Asis LB, Yasuda K, Murayama M, Mune T, Morita H, Miura K (1992) Beneficial effects of high daily dose bromocriptine treatment in Cushing\u2019s disease. Endocrinol Jpn 39:385\u2013395","journal-title":"Endocrinol Jpn"},{"key":"475_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1210\/jcem-51-2-307","volume":"51","author":"SW Lamberts","year":"1980","unstructured":"Lamberts SW, Klijn JG, de Quijada M, Timmermans HA, Uitterlinden P, de Jong FH, Birkenh\u00e4ger JC (1980) The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing\u2019s disease and Nelson\u2019s syndrome. J Clin Endocrinol Metab 51:307\u2013311","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000023539","volume":"53","author":"A Colao","year":"2000","unstructured":"Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B, Lombardi G (2000) New medical approaches in pituitary adenomas. Horm Res 53:76\u201387","journal-title":"Horm Res"},{"key":"475_CR24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000317716","volume":"92","author":"P Petrossians","year":"2010","unstructured":"Petrossians P, Thonnard AS, Beckers A (2010) Medical treatment in Cushing\u2019s syndrome: dopamine agonists and cabergoline. Neuroendocrinology 92:116\u2013119","journal-title":"Neuroendocrinology"},{"key":"475_CR25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur J Endocrinol 163:709\u2013716","journal-title":"Eur J Endocrinol"},{"key":"475_CR26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4158\/EP10031.OR","volume":"16","author":"AR Lila","year":"2010","unstructured":"Lila AR, Gopal RA, Acharya SV, George J, Sarathi V, Bandgar T, Menon PS, Shah NS (2010) Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract 16:968\u2013976","journal-title":"Endocr Pract"},{"key":"475_CR27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2265.1991.tb03516.x","volume":"35","author":"D Engelhardt","year":"1991","unstructured":"Engelhardt D, Weber MM, Miksch T, Abedinpour F, Jaspers C (1991) The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol (Oxf) 35:163\u2013168","journal-title":"Clin Endocrinol (Oxf)"},{"key":"475_CR28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0889-8529(05)70064-5","volume":"28","author":"N Sonino","year":"1999","unstructured":"Sonino N, Boscaro M (1999) Medical therapy for Cushing\u2019s disease. Endocrinol Metab Clin North Am 28:211\u2013222","journal-title":"Endocrinol Metab Clin North Am"},{"key":"475_CR29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","volume":"35","author":"N Sonino","year":"1991","unstructured":"Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D (1991) Ketoconazole treatment in Cushing\u2019s syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 35:347\u2013352","journal-title":"Clin Endocrinol (Oxf)"},{"key":"475_CR30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","volume":"158","author":"F Castinetti","year":"2008","unstructured":"Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease. Eur J Endocrinol 158:91\u201399","journal-title":"Eur J Endocrinol"},{"key":"475_CR31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1677\/JME-08-0110","volume":"42","author":"C Bruin de","year":"2009","unstructured":"de Bruin C, Feelders RA, Waaijers AM, van Koetsveld PM, Sprij-Mooij DM, Lamberts SW, Hofland LJ (2009) Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol 42:47\u201356","journal-title":"J Mol Endocrinol"},{"key":"475_CR32","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2008-2101","volume":"94","author":"C Bruin de","year":"2009","unstructured":"de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, van der Lelij AJ, de Herder WW, Lamberts SW, Hofland LJ (2009) Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 94:1118\u20131124","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR33","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1210\/jc.2008-1171","volume":"93","author":"CA Carrasco","year":"2008","unstructured":"Carrasco CA, Coste J, Guignat L, Groussin L, Dugu\u00e9 MA, Gaillard S, Bertagna X, Bertherat J (2008) Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing\u2019s disease. J Clin Endocrinol Metab 93:4728\u20134734","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR34","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1210\/jc.2009-1166","volume":"94","author":"H Raff","year":"2009","unstructured":"Raff H (2009) Utility of salivary cortisol measurements in Cushing\u2019s syndrome and adrenal insufficiency. J Clin Endocrinol Metab 94:3647\u20133655","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR35","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1210\/jc.2008-1542","volume":"94","author":"ML Nunes","year":"2009","unstructured":"Nunes ML, Vattaut S, Corcuff JB, Rault A, Loiseau H, Gatta B, Valli N, Letenneur L, Tabarin A (2009) Late-night salivary cortisol for diagnosis of overt and subclinical Cushing\u2019s syndrome in hospitalized and ambulatory patients. J Clin Endocrinol Metab 94:456\u2013462","journal-title":"J Clin Endocrinol Metab"},{"key":"475_CR36","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1530\/EJE-11-0424","volume":"165","author":"R Bou Khalil","year":"2011","unstructured":"Bou Khalil R, Baudry C, Guignat L, Carrasco C, Guibourdenche J, Gaillard S, Bertagna X, Bertherat J (2011) Sequential hormonal changes in 21 patients with recurrent Cushing\u2019s disease after successful pituitary surgery. Eur J Endocrinol 165:729\u2013737","journal-title":"Eur J Endocrinol"},{"key":"475_CR37","author":"R Pas van der","year":"2012","unstructured":"van der Pas R, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Webb SM, Lamberts SW, Hofland LJ, Feelders RA (2012) Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing\u2019s disease. Pituitary doi. doi: 10.1007\/211102-012-0452-2","journal-title":"Pituitary doi"},{"key":"475_CR38","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/sj.jhh.1000987","volume":"14","author":"MB Murphy","year":"2000","unstructured":"Murphy MB (2000) Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 14:S47\u2013S50","journal-title":"J Hum Hypertens"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-013-0475-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-013-0475-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-013-0475-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T06:08:17Z","timestamp":1559369297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-013-0475-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,7]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1007\/s11102-013-0475-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,7]]}}}